CST BLOG: Lab Expectations

The official blog of Cell Signaling Technology® (CST) where we discuss what to expect from your time at the bench, share tips, tricks, and information.

All Posts

2018 Nobel Prize Awarded to Immunotherapy Pioneers

Earlier this week, Dr. James Allison and Dr. Tasuku Honjo were announced as joint winners of the 2018 Nobel Prize in Physiology or Medicine for their work in the field of immunotherapy and checkpoint immune regulation. Their studies have sparked decades of clinical advances, and changed the future of cancer therapy. A webinar presented by Dr. Allison in conjunction with Dr. Gordon Freeman and Dr. Philip Gotwals is featured in this week's blog post.

Targeting Cancer Pathways: Understanding Immune Checkpoints webinar

 

 

In this webinar, we explore how tumors exploit immune modulatory mechanisms to generate and thrive in their own immunosuppressive microenvironment. Further, we examine how these mechanisms can be targeted to develop better therapeutic options. This webinar also includes:

  • A historical overview of immune checkpoint research and examination of the effect of mutational load on clinical response.
  • Explanation of how PD-1 immunotherapy stops certain cancers from turning off the anticancer immune response.
  • Discussion of general therapeutic approaches to activating the immune system to treat cancer.

Interested in exploring Immune Checkpoint Signaling? Check out this interactive pathway:

Immune Checkpoint Signaling Interactive Pathway

Related Posts

Novel Therapeutic Approaches for Diffuse Large B Cell Lymphoma

Lymphoma is a cancer of the lymphatic system, a principal part of the body’s immune system. Lymphoma most...
Andrea T May 11, 2022 3:00:00 AM

Pancreatic Cancer: Targeting Novel Drivers in the TME

  Pancreatic cancer is devastating and difficult to diagnose early. The organ is located deep inside the ...
Andrea T Apr 27, 2022 3:00:00 AM

CST Joins 1% for the Planet

Long before our founder and CEO began producing antibodies for researchers around the globe, he was enjoy...
Chris S Apr 19, 2022 3:00:00 AM